TheStreet home
TheStreet home
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTCRYPTOMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTERTECHNOLOGY
Search

David Sobek

Articles From This Author

Could This Biotech Stock Be First to Break Feuerstein-Ratain Rule?
STOCKS

Gilead Buying Vertex Among Bold Biotech Stock Predictions for 2015

Looking at Mannkind's Afrezza Sales Estimates Ahead of Sanofi Earnings
STOCKS

2014 Healthcare Stock Report Card: Sobek Tracks His Hits and Misses

Genfit Digs Even Deeper to Find Hidden Benefit in Fatty Liver Drug
STOCKS

Foundation Medicine Winning Increased Insurance Coverage for Genetic Cancer Tests

Looking at Mannkind's Afrezza Sales Estimates Ahead of Sanofi Earnings
STOCKS

Strong Prostate Cancer Drug Sales Will Help Medivation Expand Pipeline

Genfit Digs Even Deeper to Find Hidden Benefit in Fatty Liver Drug
STOCKS

Stock Weakness in Seattle Genetics, Gilead Sciences Belies Fundamental Strengths

Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest
STOCKS

Acceleron Hit Over Competitive Concerns, but Investors Overlook Rest of Pipeline

Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie
STOCKS

Safety Worries Over Celgene's Experimental Crohn's Drug Overblown

Gilead: Hepatitis C Sales Guidance for 2015 Focus of Tuesday's Earnings Report
STOCKS

Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity

Looking at Mannkind's Afrezza Sales Estimates Ahead of Sanofi Earnings
STOCKS

Tetraphase Oral Antibiotic Data Look Good

Could This Biotech Stock Be First to Break Feuerstein-Ratain Rule?
STOCKS

Previewing Tetraphase Oral Antibiotic Study Results

Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest
STOCKS

Epizyme First Look at Blood Cancer Drug Encourages

Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point
STOCKS

Pharmacyclics Has Edge Over Blood Cancer Competitors

Biotech Stock Mailbag: Biogen's Alzheimer's Update, Celgene Patent Worries, Receptos, MannKind
STOCKS

Biotech Valuations Are Low Not Stretched. Here's Why.

CTI Biopharma Posts Positive Myelofibrosis Study Results
STOCKS

Seattle Genetics Nearing Key Test for Investor Confidence

MannKind Afrezza Contributes to Sanofi's Subpar Diabetes Unit Sales
STOCKS

Grading Sobek's Mid-Year Biotech Stock Predictions

Genfit Tortures Fatty Liver Drug to Extract Positive Results From Failed Study
STOCKS

Closer Look at Gilead's Slowing Hep C Prescriptions

Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest
STOCKS

Incyte's Jakafi Unlikely to Benefit Pancreatic Cancer Patients

Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest
STOCKS

ASCO '14: Foundation Medicine Builds Case for Insurance Coverage

Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie
STOCKS

Bull Thesis on Foundation Medicine: Using Big Data to Improve Treatment Decisions for Cancer Patients

Looking at Mannkind's Afrezza Sales Estimates Ahead of Sanofi Earnings
STOCKS

The Bull Thesis for Pharmacyclics Into ASCO '14

MannKind Afrezza Contributes to Sanofi's Subpar Diabetes Unit Sales
STOCKS

Merrimack Pharma and the Marginal Benefit of Pancreatic Cancer Drug MM-398

Genfit Tortures Fatty Liver Drug to Extract Positive Results From Failed Study
STOCKS

Fear Not, Biotech Stock 'Correction' Is Not a Bursting Bubble

Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie
STOCKS

Anacor Pharma Remains Over-Valued on Development of Inferior Drugs

Could This Biotech Stock Be First to Break Feuerstein-Ratain Rule?
STOCKS

Conatus Pharma Deserves a Look by Investors in Love With Liver Disease Stocks

Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point
STOCKS

Tetraphase Antibiotic Nearing Key Tolerability Test

MannKind Afrezza Contributes to Sanofi's Subpar Diabetes Unit Sales
STOCKS

Endocyte Bulls Were Right, But Bears Aren't Going Away

CTI Biopharma Posts Positive Myelofibrosis Study Results
STOCKS

Onconova's MDS Study Fails and I Explain What I Got Wrong.

Could This Biotech Stock Be First to Break Feuerstein-Ratain Rule?
STOCKS

Cempra Antibiotic Candidate Clears Important Heart Safety Hurdle

Genfit Tortures Fatty Liver Drug to Extract Positive Results From Failed Study
STOCKS

Cancer Immunotherapy Combos: The Future Despite Fuzzy Road Map

CTI Biopharma Posts Positive Myelofibrosis Study Results
STOCKS

The State of Gene Therapy in a Biogen Idec World: Sangamo, Bluebird and Acceleron

MannKind Afrezza Contributes to Sanofi's Subpar Diabetes Unit Sales
STOCKS

The French Cancer Immunotherapy Stock Investors Don't Know, But Really Should

MannKind Afrezza Contributes to Sanofi's Subpar Diabetes Unit Sales
STOCKS

Why Investors Are Writing Off Infinity Pharma

Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie
STOCKS

Biotech Stock Predictions 2014: Vertex is Bought, Alexion Sinks, BlueBird Flies And More

Could This Biotech Stock Be First to Break Feuerstein-Ratain Rule?
STOCKS

Four Biotech 'Surprise' Stocks for 2014

Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie
STOCKS

Onconova Weakness Improves Risk-Reward Heading Into Pivotal Study Results

Gilead: Hepatitis C Sales Guidance for 2015 Focus of Tuesday's Earnings Report
STOCKS

Celgene's Revlimid Makes Stronger Case for European Front-Line Approval

Ampio's Eye Drug Approval Strategy Dealt Another Credibility Hit
STOCKS

Odds Favor Endocyte Receiving European Approval For Ovarian Cancer Drug

AbbVie Deserves More Respect
STOCKS

3 Antibiotic Stocks Targeting Most Urgent Bacterial Threats

Ampio's Eye Drug Approval Strategy Dealt Another Credibility Hit
STOCKS

I Was Wrong About Ariad Pharma and Here's Why

Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie
STOCKS

Biotech Stock Bubble Talk Deflated By Cost-Conscious Buyers

Galapagos Receives a Rousing Welcome on Its First Day of Trading
STOCKS

Making The Call: Onconova MDS Drug Study Will Succeed

One Short Seller's Take On Arena's Slow Belviq Launch
STOCKS

Ariad Pharma: Dismantling The Short Thesis

Steve Rosenman Says Amarin Has Sticky Web Eyeballs!
STOCKS

Why Sangamo Was Smart To Buy Ceregene

Horizon Goes Hostile With $3 Billion Takeout Offer for Depomed
STOCKS

Merck Hopes Alzheimer's Drug Fares Better Than Competitors

Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest
STOCKS

Alimera, pSivida Eye Drug Warrants FDA Approval On Third Try

One Short Seller's Take On Arena's Slow Belviq Launch
STOCKS

Anacor: Overvalued On Weak Drug Pipeline

One Short Seller's Take On Arena's Slow Belviq Launch
STOCKS

Tetraphase: Another Good Investment In Hot Antibiotic Market

Horizon Goes Hostile With $3 Billion Takeout Offer for Depomed
STOCKS

Ariad Pharma: Three Hurdles For Long-Term Win

Steve Rosenman Says Amarin Has Sticky Web Eyeballs!
STOCKS

Spectrum Can Generate Profits From Misfit Cancer Drugs

Genfit Tortures Fatty Liver Drug to Extract Positive Results From Failed Study
STOCKS

Five Keys to Making a Cancer Smart Bomb Go 'BOOM!'